Bellicum Pharmaceuticals, Inc. (BLCM) Shares Gap Up to $10.80

Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) gapped up before the market opened on Friday . The stock had previously closed at $10.34, but opened at $10.80. Bellicum Pharmaceuticals shares last traded at $11.72, with a volume of 2,003,420 shares changing hands.

BLCM has been the subject of several analyst reports. Ladenburg Thalmann Financial Services set a $31.00 price target on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald set a $32.00 price target on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Wells Fargo & Company reissued an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Raymond James Financial, Inc. reissued a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Finally, BidaskClub lowered shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Bellicum Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $26.20.

The company’s market capitalization is $389.41 million. The company’s 50-day moving average is $9.50 and its 200 day moving average is $11.71.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period in the previous year, the firm posted ($0.61) EPS. On average, equities research analysts anticipate that Bellicum Pharmaceuticals, Inc. will post ($3.02) earnings per share for the current fiscal year.

In related news, insider David M. Spencer sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 10th. The stock was sold at an average price of $11.54, for a total transaction of $115,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Ken Moseley sold 13,823 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now owns 14,314 shares of the company’s stock, valued at approximately $175,489.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,260 shares of company stock valued at $290,048. 23.30% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. lifted its stake in Bellicum Pharmaceuticals by 0.7% during the first quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock worth $1,029,000 after purchasing an additional 610 shares during the last quarter. American International Group Inc. lifted its stake in Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 852 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Bellicum Pharmaceuticals by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 935 shares during the last quarter. Teachers Advisors LLC lifted its stake in Bellicum Pharmaceuticals by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 1,844 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in Bellicum Pharmaceuticals by 14.9% in the second quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 2,513 shares during the last quarter. Hedge funds and other institutional investors own 55.73% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/15/bellicum-pharmaceuticals-inc-blcm-shares-gap-up-to-10-80.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply